Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.

MLA

Sasaki, Koji, et al. “Impact of the Variant Allele Frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia.” Cancer (0008543X), vol. 126, no. 4, Feb. 2020, pp. 765–74. EBSCOhost, https://doi.org/10.1002/cncr.32566.

APA

Sasaki, K., Kanagal, S. R., Montalban, B. G., Assi, R., Jabbour, E., Ravandi, F., Kadia, T., Pierce, S., Takahashi, K., Nogueras Gonzalez, G., Patel, K., Soltysiak, K. A., Cortes, J., Kantarjian, H. M., Garcia, M. G., Kanagal-Shamanna, R., Montalban-Bravo, G., & Garcia-Manero, G. (2020). Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer (0008543X), 126(4), 765–774. https://doi.org/10.1002/cncr.32566

Chicago

Sasaki, Koji, Shamanna, Rashmi Kanagal, Bravo, Guillermo Montalban, Rita Assi, Elias Jabbour, Farhad Ravandi, Tapan Kadia, et al. 2020. “Impact of the Variant Allele Frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia.” Cancer (0008543X) 126 (4): 765–74. doi:10.1002/cncr.32566.